Logo image of ARVN

ARVINAS INC (ARVN) Stock Fundamental Analysis

NASDAQ:ARVN - Nasdaq - US04335A1051 - Common Stock - Currency: USD

6.99  -0.24 (-3.32%)

Fundamental Rating

3

Overall ARVN gets a fundamental rating of 3 out of 10. We evaluated ARVN against 198 industry peers in the Pharmaceuticals industry. The financial health of ARVN is average, but there are quite some concerns on its profitability. ARVN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ARVN had negative earnings in the past year.
ARVN had a negative operating cash flow in the past year.
ARVN had negative earnings in each of the past 5 years.
In the past 5 years ARVN reported 4 times negative operating cash flow.
ARVN Yearly Net Income VS EBIT VS OCF VS FCFARVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

1.2 Ratios

ARVN's Return On Assets of -18.22% is fine compared to the rest of the industry. ARVN outperforms 63.13% of its industry peers.
Looking at the Return On Equity, with a value of -35.41%, ARVN is in line with its industry, outperforming 59.60% of the companies in the same industry.
Industry RankSector Rank
ROA -18.22%
ROE -35.41%
ROIC N/A
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.02%
ROE(5y)-36.82%
ROIC(3y)N/A
ROIC(5y)N/A
ARVN Yearly ROA, ROE, ROICARVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K

1.3 Margins

ARVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARVN Yearly Profit, Operating, Gross MarginsARVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

ARVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARVN has been increased compared to 1 year ago.
The number of shares outstanding for ARVN has been increased compared to 5 years ago.
Compared to 1 year ago, ARVN has an improved debt to assets ratio.
ARVN Yearly Shares OutstandingARVN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ARVN Yearly Total Debt VS Total AssetsARVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -1.00, we must say that ARVN is in the distress zone and has some risk of bankruptcy.
ARVN has a Altman-Z score (-1.00) which is comparable to the rest of the industry.
ARVN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.00, ARVN is doing good in the industry, outperforming 63.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1
ROIC/WACCN/A
WACC9.51%
ARVN Yearly LT Debt VS Equity VS FCFARVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

ARVN has a Current Ratio of 4.64. This indicates that ARVN is financially healthy and has no problem in meeting its short term obligations.
ARVN has a better Current ratio (4.64) than 70.71% of its industry peers.
A Quick Ratio of 4.64 indicates that ARVN has no problem at all paying its short term obligations.
ARVN has a better Quick ratio (4.64) than 72.22% of its industry peers.
Industry RankSector Rank
Current Ratio 4.64
Quick Ratio 4.64
ARVN Yearly Current Assets VS Current LiabilitesARVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.87% over the past year.
ARVN shows a strong growth in Revenue. In the last year, the Revenue has grown by 235.54%.
Measured over the past years, ARVN shows a very strong growth in Revenue. The Revenue has been growing by 43.69% on average per year.
EPS 1Y (TTM)88.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%217.53%
Revenue 1Y (TTM)235.54%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%646.25%

3.2 Future

Based on estimates for the next years, ARVN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.02% on average per year.
ARVN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.52% yearly.
EPS Next Y-41.53%
EPS Next 2Y-24.91%
EPS Next 3Y-10.69%
EPS Next 5Y15.02%
Revenue Next Year-28.23%
Revenue Next 2Y-17.9%
Revenue Next 3Y-8.78%
Revenue Next 5Y16.52%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ARVN Yearly Revenue VS EstimatesARVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ARVN Yearly EPS VS EstimatesARVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARVN. In the last year negative earnings were reported.
Also next year ARVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARVN Price Earnings VS Forward Price EarningsARVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARVN Per share dataARVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

ARVN's earnings are expected to decrease with -10.69% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.91%
EPS Next 3Y-10.69%

More info and screens

0

5. Dividend

5.1 Amount

ARVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARVINAS INC

NASDAQ:ARVN (5/2/2025, 11:15:04 AM)

6.99

-0.24 (-3.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2025-02-11/bmo
Earnings (Next)05-06 2025-05-06/bmo
Inst Owners108.55%
Inst Owner Change-0.04%
Ins Owners1.92%
Ins Owner Change3.51%
Market Cap480.70M
Analysts82.14
Price Target32.52 (365.24%)
Short Float %12.38%
Short Ratio2.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.11%
Min EPS beat(2)30.66%
Max EPS beat(2)39.55%
EPS beat(4)4
Avg EPS beat(4)36.87%
Min EPS beat(4)30.66%
Max EPS beat(4)44.34%
EPS beat(8)6
Avg EPS beat(8)13%
EPS beat(12)6
Avg EPS beat(12)0.61%
EPS beat(16)6
Avg EPS beat(16)-10.97%
Revenue beat(2)1
Avg Revenue beat(2)31.87%
Min Revenue beat(2)-11.09%
Max Revenue beat(2)74.84%
Revenue beat(4)2
Avg Revenue beat(4)17.54%
Min Revenue beat(4)-29.28%
Max Revenue beat(4)74.84%
Revenue beat(8)4
Avg Revenue beat(8)-4.27%
Revenue beat(12)7
Avg Revenue beat(12)4.38%
Revenue beat(16)10
Avg Revenue beat(16)6.88%
PT rev (1m)-45.13%
PT rev (3m)-47.55%
EPS NQ rev (1m)3.59%
EPS NQ rev (3m)26.49%
EPS NY rev (1m)1.9%
EPS NY rev (3m)17.01%
Revenue NQ rev (1m)-3.58%
Revenue NQ rev (3m)1.91%
Revenue NY rev (1m)-10.52%
Revenue NY rev (3m)-12.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.82
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-0.66
EYN/A
EPS(NY)-4.32
Fwd EYN/A
FCF(TTM)-3.8
FCFYN/A
OCF(TTM)-3.77
OCFYN/A
SpS3.83
BVpS8.17
TBVpS8.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.22%
ROE -35.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.02%
ROE(5y)-36.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.13%
Cap/Sales 0.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.64
Quick Ratio 4.64
Altman-Z -1
F-Score4
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)69.16%
Cap/Depr(5y)101.08%
Cap/Sales(3y)3.18%
Cap/Sales(5y)9.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%217.53%
EPS Next Y-41.53%
EPS Next 2Y-24.91%
EPS Next 3Y-10.69%
EPS Next 5Y15.02%
Revenue 1Y (TTM)235.54%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%646.25%
Revenue Next Year-28.23%
Revenue Next 2Y-17.9%
Revenue Next 3Y-8.78%
Revenue Next 5Y16.52%
EBIT growth 1Y60.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.19%
EBIT Next 3Y2.07%
EBIT Next 5YN/A
FCF growth 1Y25.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.45%
OCF growth 3YN/A
OCF growth 5YN/A